Gara Jalqabaatti › Kansaar Onnee Triple-Negative › California › San Francisco
Qorannoo klinikaalii Kansaar Onnee Triple-Negative San Francisco, CA keessatti
Qorannoo 11 Kansaar Onnee Triple-Negative f San Francisco fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Namoota walitti qabaa jiraSadarkaa 3
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Namoota walitti qabaa jiraSadarkaa 3
- Kaiser Permanente - San Francisco ( Site 0080), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California, San Francisco, San Francisco
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Namoota walitti qabaa jiraSadarkaa 3
- City of Hope (Duarte), San Francisco
- UCSF Medical Center, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of California, San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of California San Francisco (UCSF), San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Namoota walitti qabaa jiraSadarkaa 2
- University of California San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- University of California, San Francisco, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
Namoota walitti qabaa jiraQorannoo ilaalaa
- Curebase, San Francisco
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Los Angeles, CAQorannoo 27
- Boston, MAQorannoo 26
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Chicago, ILQorannoo 16
- Columbus, OHQorannoo 16
Qorannoo biroo San Francisco keessatti
- Kansarii ProstateQorannoo 45
- Saree OljooQorannoo 43
- Kansara Qara'a Non-Small CellQorannoo 36
- Saree (Gosoota Hunda)Qorannoo 35
- Cufama OnneeQorannoo 29
- Kansara MetastatikiiQorannoo 28
- Dhibee QaraQorannoo 22
- MelanomaQorannoo 22
- Kansarii PancreasQorannoo 20
- Kansarii OvariiQorannoo 19
- Kansarii ColorectalQorannoo 18
- Dhibee Onneessaa fi DhiigaQorannoo 18
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.